This site is currently not optimized for mobile devices. For the best user experience, please access the site via a device with a wider screen such as a desktop or laptop.

For full functionality of this site it is necessary to enable JavaScript. Here are the instructions how to enable JavaScript in your web browser.

Once enabled, click here to view the site.

signup link button why should I sign up?
Login as Volunteer Login as Study team member
OR

Studies you may be eligible for. 8

Based on the information you provided, we found the following studies.

  • An Open-label, Phase 1b Study of ACP-196 Alone or in Combination with Rituximab in Subjects with Follicular Lymphoma Study purpose: find out if ACP-196, given either twice daily by mouth or ACP-196 given twice daily by mouth along with Rituxan® (given as an IV infusion), will slow or stop relapsed/refractory/not previously treated follicular cancer from getting worse and whether ACP-196 has side effects. This study is researching all of the following topics: Lymphoma This study is looking for: male female both men and women Volunteers with specific conditions
    • More than 18 years old
  • A phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) Study purpose: test an experimental approach called engineered T-cell therapy for DLBCL, in which your own modified T-cells will recognize and possibly kill cells that display on their surface a protein named CD19 (including your DLBCL tumor B cells and also normal antibody producing B cells). This study is researching all of the following topics: Lymphoma This study is looking for: male female both men and women Volunteers with specific conditions
    • More than 18 years old
  • A Multi-Center Open-Label Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with MEDI4736, in Subjects with Relapsed or Refractory Lymphomas To learn how two experimental drugs called ibrutinib and MEDI4736, when given together, will work on treating your cancer. A possible participant would have received at least one prior treatment for the cancer and the cancer has either stayed stable or worsened during or after your last treatment. This study is researching all of the following topics: Lymphoma This study is looking for: male female both men and women Volunteers with specific conditions
    • More than 18 years old
  • Phase 1 Dose Escalation w/Two Disease Specific Expansions, Open-Label, Safety, Pharmacokinetic and Pharmacodynamic Study of APTO-253 in Patients with Relapsed or Refractory Hematologic Malignancies Study Purpose: test the safety of APTO-253; find the maximum dose of APTO-253 which can be tolerated when given two times a week; find out what effects, good and/or bad, this treatment has on you and your cancer and how APTO-253 may work in the body and your body's ability to get rid of APTO-253. This study is researching all of the following topics: ALL ( Acute lymphoblastic leukemia ) AML ( Acute myeloid leukemia ) Hodgkin's lymphoma Leukemia Lymphoma MDS ( Myelodysplastic syndrome ) Multiple myeloma Non-Hodgkin's lymphoma This study is looking for: male female both men and women Volunteers with specific conditions
    • More than 18 years old
  • Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and Graft-versus-host Disease in Allogeneic Hematopoietic Cell Transplantation for High-risk Hematologic Malignancies Investigational drug carfilzomib will be added to a standard chemotherapy conditioning regimen for donor blood stem cell transplant to test if this new conditioning regimen can lead to safe and more effective stem cell transplant treatment approach for patients with quickly worsening blood cancers. This study is researching all of the following topics: ALL ( Acute lymphoblastic leukemia ) AML ( Acute myeloid leukemia ) Amyloidosis CLL ( Chronic lymphocytic leukemia) Leukemia Lymphoma MDS ( Myelodysplastic syndrome ) Multiple myeloma Myelofibrosis Non-Hodgkin's lymphoma This study is looking for: male female both men and women Volunteers with specific conditions
    • Less than 66 years old
    • More than 18 years old
  • Open-label, single-center phase II study of MLN9708 (Ixazomib) in patients with relapsed/refractory cutaneous and peripheral T-cell Lymphomas The main purpose of this study is to determine if MLN9708, an investigational drug, will work against cutaneous or peripheral T-cell lymphoma that has failed to respond to other treatments, and to evaluate its side effects. This study is researching all of the following topics: Lymphoma This study is looking for: male female both men and women Volunteers with specific conditions
    • More than 18 years old
  • Phase I safety study of intratumoral injection of Clostridium novyi-NT spores in patients with treatment-refractory solid tumor malignancies This study is being done to learn whether treatment with Clostridium novyi-NT spores (NT refers to non-toxin producing) is safe and effective in patients with advanced cancers that can no longer be controlled with standard therapy or cancers for which there is no standard effective treatment. This study is researching all of the following topics: Adrenal cancer BCC, Basal cell skin cancer Bladder cancer Bone cancer Breast cancer Cervical cancer Colon Cancer ( Malignant tumor of colon ) Esophagus cancer Fallopian tube cancer HCC, Liver cancer Kidney Cancer ( Malignant tumor of kidney ) Laryngeal cancer, Cancer of the larynx, Voice box cancer Lung cancer Lymphoma NPC, Nasal cancer Oral / Mouth cancer Ovarian cancer Pancreatic cancer Prostate cancer Salivary Gland Cancer Sarcoma Squamous cell skin cancer Thyroid cancer Uterine / Uterus cancer This study is looking for: male female both men and women Volunteers with specific conditions
    • More than 18 years old
  • A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, in Combination with Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lymphoma Experimental drug Ibrutinib is being tested to see if it may be useful in treating patients with newly diagnosed Mantle Cell Lymphoma.The study purpose is to compare the effects of Ibrutinib when it is given with Bendamustine (Treanda) and Rituximab (Rituxan) to Bendamustine and Rituximab alone. This study is researching all of the following topics: Lymphoma This study is looking for: male female both men and women Volunteers with specific conditions
    • More than 18 years old